Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain

NeuroToxicology

Volumn 28, Issue 6, 2007, Pages 1158-1169

  Kindlundh Högberg, Anna M S ^a,b   Schiöth, Helgi B ^b   Svenningsson, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

3,4 Methylenedioxymethamphetamine (MDMA); Autoradiography; Dopamine transporter; Drug abuse; Ecstasy; Serotonin transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE RECEPTOR; SEROTONIN RECEPTOR;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR CHANGE; BRAIN REGION; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG INTERMITTENT THERAPY; DRUG REEXPOSURE; IMPULSIVENESS; LIGAND BINDING; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; REWARD; SEROTONIN UPTAKE; SEROTONINERGIC TRANSMISSION;

AGE FACTORS; AGING; ANIMALS; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; IMPULSIVE BEHAVIOR; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; REWARD; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SPECIES SPECIFICITY; TIME FACTORS;

MUS; RATTUS;

EID: 35648964135     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2007.07.002     Document Type: Article

References (60)

1. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
2. Berridge K.C., and Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res Brain Res Rev 28 (1998) 309-369
3. Camarero J., Sanchez V., O'Shea E., Green A.R., and Colado M.I. Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. J Neurochem 81 (2002) 961-972
4. Check E. Psychedelic drugs: the ups and downs of ecstasy. Nature 429 (2004) 126-128
5. Colado M.I., Camarero J., Mechan A.O., Sanchez V., Esteban B., Elliott J.M., et al. A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br J Pharmacol 134 (2001) 1711-1723
6. Cole J.C., and Sumnall H.R. Altered states: the clinical effects of ecstasy. Pharmacol Ther 98 (2003) 35-58
7. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 375 (1999) 13-30
8. Everitt B.J., Parkinson J.A., Olmstead M.C., Arroyo M., Robledo P., and Robbins T.W. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci 877 (1999) 412-438
9. Geyer M.A. Serotonergic functions in arousal and motor activity. Behav Brain Res 73 (1996) 31-35
10. Giros B., and Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14 (1993) 43-49
11. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55 (2003) 463-508
12. Gudelsky G.A., and Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66 (1996) 243-249
13. Han D.D., and Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6 (2006) 6
14. Jacobs B.L., and Fornal C.A. Activity of serotonergic neurons in behaving animals. Neuropsychopharmacology 21 (1999) 9S-15S
15. Kalivas P.W., Duffy P., and White S.R. MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 18 (1998) 469-479
16. Kindlundh-Hogberg A.M., Svenningsson P., and Schioth H.B. Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain. Neuropharmacology 51 (2006) 838-847
17. Koch S., and Galloway M.P. MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104 (1997) 135-146
18. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13 (1992) 177-184
19. Koob G.F., and Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24 (2001) 97-129
20. Kreek M.J., Nielsen D.A., Butelman E.R., and LaForge K.S. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8 (2005) 1450-1457
21. Liechti M.E., and Vollenweider F.X. Acute psychological and physiological effects of MDMA ("ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10 (2000) 289-295
22. Linnoila M., Virkkunen M., Scheinin M., Nuutila A., Rimon R., and Goodwin F.K. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 33 (1983) 2609-2614
23. Logan B.J., Laverty R., Sanderson W.D., and Yee Y.B. Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. Eur J Pharmacol 152 (1988) 227-234
24. McCreary A.C., Bankson M.G., and Cunningham K.A. Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. J Pharmacol Exp Ther 290 (1999) 965-973
25. McGregor I.S., Clemens K.J., Van der Plasse G., Li K.M., Hunt G.E., Chen F., et al. Increased anxiety 3 months after brief exposure to MDMA ("ecstasy") in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28 (2003) 1472-1484
26. Morgan M.J. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19 (1998) 252-264
27. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 5 (2005) 79-86
28. Nestler E.J., and Aghajanian G.K. Molecular and cellular basis of addiction. Science 278 (1997) 58-63
29. O'Callaghan J.P., and Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270 (1994) 741-751
30. Oreland L. Monoamine oxidase in neuro-pscychiatric disorders. In: Yasuhara H., Parvez S.H., Oguchi K., Sandler M., and Nagatsu T. (Eds). Monoamine oxidase: basic and clinical aspects (1993), VSP Press, Utrecht 219-247
31. O'Shea E., Esteban B., Camarero J., Green A.R., and Colado M.I. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40 (2001) 65-74
32. O'Shea E., Granados R., Esteban B., Colado M.I., and Green A.R. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37 (1998) 919-926
33. Parrott A.C. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71 (2002) 837-844
34. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 3rd ed. (1997), Academic Press, Inc.
35. Piper B.J. A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol Teratol 29 (2007) 288-300
36. Piper B.J., and Meyer J.S. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav 79 (2004) 723-731
37. Pontieri F.E., Tanda G., and Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad Sci USA 92 (1995) 12304-12308
38. Powell S.B., Lehmann-Masten V.D., Paulus M.P., Gainetdinov R.R., Caron M.G., and Geyer M.A. MDMA "ecstasy" alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology (Berl) 173 (2004) 310-317
39. Ramos M., Goni-Allo B., and Aguirre N. Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats: an effect mediated by 5-HT(2C) receptor stimulation and not by D(1) receptor blockade. Neuropsychopharmacology 30 (2005) 2180-2191
40. Rothman R.B., and Baumann M.H. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479 (2003) 23-40
41. Ryabinin A.E., Wang Y.M., and Finn D.A. Different levels of Fos immunoreactivity after repeated handling and injection stress in two inbred strains of mice. Pharmacol Biochem Behav 63 (1999) 143-151
42. Scearce-Levie K., Lucas J., Castanon N., Segu L., Arango V., and Hen R. Dopaminergic compensations in knockout mice lacking the serotonin 1B receptor. Society for Neuroscience, 27th Annual Meeting (1997), Society for Neuroscience, New Orleans, LA 202.2
43. Scearce-Levie K., Viswanathan S.S., and Hen R. Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology (Berl) 141 (1999) 154-161
44. Schechter M.D. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Biochem Behav 31 (1988) 817-824
45. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 80 (1998) 1-27
46. Soderpalm B., and Svensson A.I. Naloxone reverses disinhibitory/aggressive behavior in 5,7-DHT-lesioned rats; involvement of GABA(A) receptor blockade?. Neuropharmacology 38 (1999) 1851-1859
47. Spanagel R., and Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 22 (1999) 521-527
48. Spanos L.J., and Yamamoto B.K. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 32 (1989) 835-840
49. Steinbusch H.M.W. Serotonin immunoreactive neurons and their projections in the CNS. In: Björklund A., and Hökfelt T. (Eds). Handbook of chemical neuroanatomy. Classical transmitters and transmitter receptors in the CNS. Part II (1984), Elsevier, Amsterdam 68-125
50. Stone D.M., Hanson G.R., and Gibb J.W. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26 (1987) 1657-1661
51. Treit D., and Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 31 (1988) 959-962
52. Trigo J.M., Panayi F., Soria G., Maldonado R., and Robledo P. A reliable model of intravenous MDMA self-administration in naive mice. Psychopharmacology (Berl) 184 (2006) 212-220
53. Tye N.C., Everitt B.J., and Iversen S.D. 5-Hydroxytryptamine and punishment. Nature 268 (1977) 741-743
54. Ungerstedt U. Stereotaxic mapping of monoamine pathways in the rat brain. Acta Physiol Scand Suppl 367 (1971) 1-48
55. von Knorring L., Oreland L., and Winblad B. Personality traits related to monoamine oxidase activity in platelets. Psychiatry Res 12 (1984) 11-26
56. White S.R., Duffy P., and Kalivas P.W. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience 62 (1994) 41-50
57. Winstanley C.A., Dalley J.W., Theobald D.E., and Robbins T.W. Fractionating impulsivity: contrasting effects of central 5-HT depletion on different measures of impulsive behavior. Neuropsychopharmacology 29 (2004) 1331-1343
58. Wise R.A., and Bozarth M.A. Brain mechanisms of drug reward and euphoria. Psychiatr Med 3 (1985) 445-460
59. Yamamoto B.K., and Spanos L.J. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148 (1988) 195-203
60. Zhang L., Shirayama Y., Shimizu E., Iyo M., and Hashimoto K. Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol 544 (2006) 1-9